Not yet recruiting
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
NCT07234877· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source
Not yet recruiting
A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy
2026-527617-29-00· Phase 3· Systimmune Inc.· Source
Recruiting
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Hoffmann-La Roche· Source
Recruiting
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07509307· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07481630· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· Phase 3· Bristol-Myers Squibb· Source
Recruiting
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865· Phase 3· Vor Biopharma· Source
Recruiting
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
NCT07095465· Phase 3· ACADIA Pharmaceuticals Inc.· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· Phase 3· Amgen Inc.· Source
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Adult Participants with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
2024-518586-10-00· Phase 2/3· AbbVie Deutschland GmbH & Co. KG· Source
Recruiting
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
NCT07029581· Phase 2· ACADIA Pharmaceuticals Inc.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
2024-517529-26-00· Phase 3· Dianthus Therapeutics Inc.· Source
Recruiting
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
NCT07284121· Hoffmann-La Roche· Source
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06961214· Phase 3· GlaxoSmithKline· Source
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531· Phase 3· Astellas Pharma Global Development, Inc.· Source
Recruiting
Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures
2024-514499-42-00· Phase 3· Neuraxpharm Pharmaceuticals S.L.· Source
Active, not recruiting
A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus
2024-510584-37-00· Phase 2· Zenas Biopharma (USA) LLC· Source
Active, not recruiting
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479· Phase 2· AbbVie· Source
Active, not recruiting
Multicenter, randomized, double-blind, Phase III study of intravenous TAD® 600 mg/4 ml solution for injection to evaluate efficacy and safety in preventing myocardial injury in patients with pneumonia
2023-503950-11-00· Phase 3· Biomedica Foscama Industria Chimico-Farmaceutica S.p.A.· Source
Enrolling by invitation
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
NCT06194799· Phase 3· ACADIA Pharmaceuticals Inc.· Source
Recruiting
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806· Phase 2· Karyopharm Therapeutics Inc· Source
Contact: Luigi Rigacci
Active, not recruiting
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
NCT06408935· Phase 3· Janssen-Cilag Ltd.· Source
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566· Phase 3· Ascentage Pharma Group Inc.· Source
Active, not recruiting
Phase III Study of AK112 for NSCLC Patients
NCT06396065· Phase 3· Summit Therapeutics· Source
Recruiting
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
NCT04305548· Phase 2· Italian Sarcoma Group· Source
Enrolling by invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322· Phase 3· UCB Biopharma SRL· Source
Active, not recruiting
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389· Phase 3· Karyopharm Therapeutics Inc· Source
Active, not recruiting
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
NCT04498117· Phase 3· CanariaBio Inc.· Source
Active, not recruiting
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493· Phase 3· Epizyme, Inc.· Source
Active, not recruiting
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
SAPT Versus DAPT in Incomplete Revascularization After CABG
NCT03789916· Phase 3· Campus Bio-Medico University· Source
Contact: Antonio Nenna, MD
Active, not recruiting
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
NCT03710603· Phase 3· Stichting European Myeloma Network· Source
Active, not recruiting
MILES5 – A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC
NCT03975114· Phase 2· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Active, not recruiting
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861· Phase 3· Eisai Inc.· Source
Active, not recruiting
BEVERLY: A randomized open-label phase 3 trial comparing bevacizumab + erlotinib vs erlotinib alone as first line treatment of patients with EGFR mutated advanced non squamous non small cell lung cancer
NCT02633189· Phase 3· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source